InvestorsHub Logo
Followers 138
Posts 23125
Boards Moderated 0
Alias Born 04/08/2004

Re: A deleted message

Monday, 12/05/2022 8:59:22 PM

Monday, December 05, 2022 8:59:22 PM

Post# of 461585
ANAVEX®2-73-AD-004 Primary Endpoint – ADAS-Cog
ANAVEX®2-73 treatment was 84% more likely to improve cognition compared to placebo, by ADAS-Cog score change of -0.50 points or better at 48 weeks
• Among patients, who improved with ANAVEX®2-73 treatment, Mean ADAS-Cog score improvement -4.03 points

https://79bcf7a1-8b8e-483b-b7cf-f5c5192a6d63.usrfiles.com/ugd/79bcf7_0f2d70718aec4c2a90a37e20a5d92c2f.pdf

I bet these 84% had the normal (wild type) sigma-1 receptor rather than the 16% who probably have mutant sigma-1 receptor genes.

Good luck and GOD bless,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News